Andrew Ambrosy to Platelet Aggregation Inhibitors
This is a "connection" page, showing publications Andrew Ambrosy has written about Platelet Aggregation Inhibitors.
Connection Strength
0.747
-
Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE). Am Heart J. 2021 05; 235:54-64.
Score: 0.747